Research analysts at StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) in a research report issued to clients and investors on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock. Galmed Pharmaceuticals Stock Performance GLMD remained flat at $0.39 during trading on Thursday. The company had a […]